PT-141, also known by its pharmaceutical name bremelanotide, is a synthetic peptide that acts as an agonist at melanocortin receptors — a family of G-protein coupled receptors that regulate multiple physiological processes including pigmentation, energy metabolism, and sexual function. PT-141 holds a notable position in the research peptide literature because it has progressed through clinical development to FDA approval, providing published clinical trial evidence that anchors its research profile in registered trial data.
The research history of PT-141 begins at the University of Arizona in the 1980s, where researchers led by Mac Hadley were studying melanotropin peptides. In the course of studying Melanotan I and Melanotan II (MT-II), researchers unexpectedly observed pronounced effects on sexual arousal in male research subjects during safety studies — a finding reported in the published literature and generating substantial subsequent investigation. PT-141 was developed from this observation as a more targeted compound with reduced pigmentation activity.
PT-141 acts as an agonist at melanocortin receptor subtypes MC3R and MC4R — the central nervous system-expressed receptors, distinct from MC1R (the primary pigmentation receptor). This CNS-mediated mechanism distinguishes PT-141 mechanistically from PDE5 inhibitors such as sildenafil, which work peripherally through vascular smooth muscle relaxation. Published research has established MC4R expression in hypothalamic regions associated with both feeding behavior and sexual arousal pathways.
Bremelanotide underwent a substantial clinical development program before receiving FDA approval. The pivotal Phase 3 RECONNECT trials were published in Obstetrics and Gynecology (Simon et al., 2019) and reported statistically significant improvements in co-primary endpoints — number of satisfying sexual events and sexual desire — compared to placebo over 24 weeks. These findings formed the basis for FDA approval of bremelanotide as Vyleesi in June 2019.
Simon JA, et al. Bremelanotide for female sexual dysfunctions in premenopausal women. Obstet Gynecol. 2019;134(5):899–908.
Because PT-141 acts on CNS melanocortin receptors rather than peripheral vascular mechanisms, published researchers have proposed that it may address aspects of sexual function — including desire and motivational components — not addressed by peripherally-acting compounds. Published Phase 2 studies in male subjects demonstrated effects in a subset of men with erectile dysfunction who had not responded to PDE5 inhibitors — a finding researchers attribute to the independent CNS mechanism.
For informational purposes only. Vyleesi (bremelanotide) is an FDA-approved pharmaceutical available only through licensed medical channels. Not medical advice or dosing guidance.
